On April 3, 2017 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reported a poster titled "Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response" (Abstract ID # 1614) at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, in Washington, D.C (Press release, OncoSec Medical, APR 3, 2017, View Source [SID1234518431]). The poster included preclinical data demonstrating the latest developments of OncoSec’s gene delivery platform in a murine melanoma model. Schedule your 30 min Free 1stOncology Demo! Previous studies have shown the use of immunomodulatory cytokines is effective in the regression of a wide range of tumors. However, systemic delivery of recombinant cytokines has often resulted in life-threatening adverse effects. Intratumoral gene electrotransfer of plasmid encoded interleukin-12 (IL-12) has shown acceptable safety and efficacy profiles in regressing tumors, both preclinically and clinically.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We sought to optimize the anti-tumor immune response of our IL-12 immunotherapy platform that combines intratumoral injection of plasmid DNA coding for IL-12 and electroporation. Using a mouse model of melanoma, we were able to demonstrate that the changes made to plasmid design and to electroporation parameters can significantly increase production of IL-12, leading to an improved anti-tumor effect," said Punit Dhillon, OncoSec President and CEO. "The new IL-12 construct is the backbone of our next generation combination molecules."
Copies of the abstract are available and can be viewed on the AACR (Free AACR Whitepaper) website at View Source!/4292/presentation/6375. The poster is available in the Publications section of OncoSec’s website.